A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J.
Platt A, et al. Among authors: vasselli j.
BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.
BMC Cancer. 2015.
PMID: 25881079
Free PMC article.
Clinical Trial.